Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Pre-Tax Margin

Income before tax as a percentage of revenue.

Nanobiotix S.A.NASDAQ: NBTX

Pre-Tax Margin · Q4 FY2025 · quarter ended Dec 2025

Pre-tax margin narrows to -618.3%

Pre-tax margin was -618.3% in Q4 FY2025, down 899.3 pp from a year earlier. Over 3 fiscal years it widened by 1113.3 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-618.3%— QoQ
Last fiscal yearDec 2025
-80.8%-1027.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-899.3 pp——
1 year-1027.0 pp——
3 years+1113.3 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-80.8%
Year-over-year change
-1027.0pp

Pre-Tax Margin vs competitors

How NBTX compares with its peers on the latest reported figures

  • NBTX's FY2025 pre-tax margin of -80.8% is the 3rd highest of the 6 companies compared; the peer median is -112.0%.
  • Its year-over-year change of -1027.0 pp is the lowest of 5, against a peer median of -73.9 pp.
  • Over three fiscal years its change of +1113.3 pp compares with a peer median of +86787.1 pp.
NBTX Competitors Peer median
Pre-Tax Margin for NBTX and competitors
Company Period LTM level YoY 3-year change
BDTXBlack Diamond Therapeutics, Inc.FY202532.0% ——
PBYIPuma Biotechnology, Inc.LTM Mar 202612.8% -0.9 pp+15.5 pp
NBTXNanobiotix S.A.FY2025-80.8% -1027.0 pp+1113.3 pp
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-112.0% +645.5 pp—
KURAKura Oncology, Inc.LTM Mar 2026-411.1% -146.9 pp—
IBRXImmunityBio, Inc.LTM Sep 2026-607.9% -185.5 pp+173558.8 pp
TYRATyra Biosciences, Inc.FY2025— ——
NVCTNuvectis Pharma, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
IMMXImmix Biopharma, Inc.FY2025— ——
CADLCandel Therapeutics, Inc.FY2025— ——
Peer median (excluding NBTX) -112.0%-73.9 pp+86787.1 pp

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.65M4.78M36.21M(7.19M)29.64M
Cost of Revenue00000
Gross Profit2.65M4.78M36.21M(7.19M)29.64M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development30.38M32.64M38.4M40.54M23.12M
Selling, General & Admin19.43M17.86M22.05M20.53M20.22M
Operating Expenses55.23M51.48M62.99M61.2M40.46M
Depreciation & Amortization1.56M1.5M551K592K1.5M
EBITDA(45.61M)(44.22M)(23.69M)(67.67M)(12.07M)
EBITDA Margin-1722.9%-925.8%-65.4%941.1%-40.7%
Operating Income(52.58M)(46.7M)(26.78M)(68.39M)(10.82M)
Operating Margin-1986.4%-977.8%-74.0%951.2%-36.5%
Interest Income0256K1.22M2.63M985K
Interest Expense699.49K5.84M7.98M8.09M10.4M
Other Income / Expenses5.58M(10.33M)(12.8M)361K(13.14M)
Income Before Tax(47M)(57.03M)(39.58M)(68.03M)(23.96M)
Pre-Tax Margin-1775.5%-1194.1%-109.3%946.2%-80.8%
Income Tax Expense5K10K120K101K3K
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Net Margin-1775.7%-1194.3%-109.6%947.6%-80.8%
EPS (Basic)(1.35)(1.64)(1.08)(1.44)(0.50)
EPS (Diluted)(1.35)(1.64)(1.08)(1.44)(0.50)
Weighted Avg Shares34.73M34.85M36.76M47.27M47.82M
Weighted Avg Shares (Diluted)34.73M34.85M36.93M47.27M47.82M

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.